Back to results
US 9,896,664 B2Granted
Oncolytic rhabdovirus
AssigneeTurnstone Limited Partnership
InventorsJohn C. Bell, David F. Stojdl
Life of this patent
Estimating the term…
Abstract
Embodiments of the invention include compositions and methods related to Maraba virus and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.
Claims21
An attenuated Maraba virus comprising:
- a G protein having an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:5 and an arginine at the position corresponding to position 242 of SEQ ID NO:5.
A method of killing a hyperproliferative cell comprising contacting the cell with an isolated oncolytic Maraba virus encoding:
- a G protein having an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:5 and an arginine at the position corresponding to position 242 of SEQ ID NO:5.
A method for treating a cancer patient comprising administering an effective amount of an isolated oncolytic Maraba virus encoding:
- a G protein having an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:5 and an arginine at the position corresponding to position 242 of SEQ ID NO:5.
A composition comprising an isolated oncolytic Maraba virus having a nucleic acid segment encoding:
- a G protein having an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:5 and an arginine at the position corresponding to position 242 of SEQ ID NO:5.
Dependencies are inferred from the claim text.